Mendelian randomization analysis of immune cell populations, serum metabolites and hepatocellular carcinoma risk
Wei Shen, Yuanying Zeng
Discover Oncology · 2025
doi:10.1007/s12672-025-03037-6 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Background Hepatocellular carcinoma (HCC) remains highly lethal globally, with complex pathogenic mechanisms. This study employs Mendelian randomization (MR) to investigate causal relationships between immune cells, serum metabolites, and HCC risk. Methods A two-sample Mendelian randomization (2SMR) design was employed, based on large-scale genome-wide association studies (GWAS) databases, selecting single nucleotide polymorphisms (SNPs) strongly associated with immune cell features and plasma metabolites as genetic instrumental variables. The inverse variance weighted (IVW). method was primarily used for effect size estimation, with robustness verified through multiple sensitivity analysis methods including MR-Egger regression and weighted median method. Results MR analysis revealed three immune cell subpopulations causally associated with HCC: CD127 on CD28 + CD4 + T cells (OR = 1.31, 95% CI: 1.15–1.49), unswitched memory B cell percentage (OR = 1.57, 95% CI: 1.23–2.01). Four causal serum metabolites were identified: 5-hydroxylysine (OR = 0.64), isobutyrylcarnitine (OR = 1.67), 1-stearoyl-GPC (OR = 0.27), and glycosyl-N-tricosanoyl-sphingadienine (OR = 0.32). For plasma metabolites, four metabolites were significantly associated with HCC risk: 5-hydroxylysine (OR = 0.64), isobutyrylcarnitine (OR = 1.67), 1-stearoyl-GPC (OR = 0.27), and glycosyl-N-tricosanoyl-sphingadienine (OR = 0.32). Conclusion This multi-omics approach provides evidence for causal relationships between specific immune populations, metabolites, and HCC risk, identifying potential biomarkers and therapeutic targets for HCC prevention and treatment.
Abstract licence: CC BY-NC-ND
References31
31 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.